Suppr超能文献

结核分枝杆菌中四种氟喹诺酮类药物不同表型药敏试验方法的相关性

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.

作者信息

Coeck Nele, de Jong Bouke C, Diels Maren, de Rijk Pim, Ardizzoni Elisa, Van Deun Armand, Rigouts Leen

机构信息

Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium Department of Biomedical Sciences, Antwerp University, Antwerp, Belgium.

Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium Department of Medicine, Division of Infectious Diseases, New York University, New York, USA Vaccinology Department, Medical Research Council Unit, Fajara, The Gambia.

出版信息

J Antimicrob Chemother. 2016 May;71(5):1233-40. doi: 10.1093/jac/dkv499. Epub 2016 Feb 6.

Abstract

BACKGROUND

Molecular resistance testing fails to explain all fluoroquinolone resistance, with a continued need for a suitable rapid phenotypic drug susceptibility testing method.

OBJECTIVE

To evaluate the optimal method for phenotypic fluoroquinolone susceptibility testing.

METHODS

Using Löwenstein-Jensen medium, Middlebrook 7H11 agar, BACTEC-MGIT 960 and the resazurin microtitre plate assay, we determined susceptibility to fluoroquinolones in Mycobacterium tuberculosis and investigated cross-resistance between ofloxacin, levofloxacin, moxifloxacin and gatifloxacin. We compared MICs of all four fluoroquinolones for 91 strains on Löwenstein-Jensen (as the gold standard) with their MICs in resazurin plates, and with ofloxacin susceptibility at a single concentration in MGIT and on 7H11 agar, in addition to sequencing of the gyrAB genes.

RESULTS AND CONCLUSIONS

Applying a cut-off of 2 mg/L ofloxacin, 1 mg/L levofloxacin and 0.5 mg/L moxifloxacin and gatifloxacin in all methods, some discordance between solid medium and MGIT methods was observed, yet this tended to be explained by MICs around the cut-off. The high discordance between Löwenstein-Jensen (LJ) and resazurin plates suggests that the currently applied cut-offs for all fluoroquinolones in the resazurin method should decrease and minor changes in colour (from blue to purple) be considered as meaningful. High-level resistance in all assays to all drugs correlated well with the presence of gyrA mutations, in support of recent findings that fluoroquinolone resistance should be tested at different concentrations, as patients with lower levels of resistance may continue to benefit from high-dose fluoroquinolone-based therapy.

摘要

背景

分子耐药性检测无法解释所有氟喹诺酮类药物耐药情况,因此持续需要一种合适的快速表型药物敏感性检测方法。

目的

评估表型氟喹诺酮类药物敏感性检测的最佳方法。

方法

使用罗氏培养基、Middlebrook 7H11琼脂、BACTEC-MGIT 960和刃天青微量滴定板法,我们测定了结核分枝杆菌对氟喹诺酮类药物的敏感性,并研究了氧氟沙星、左氧氟沙星、莫西沙星和加替沙星之间的交叉耐药性。我们将91株菌株在罗氏培养基(作为金标准)上对所有四种氟喹诺酮类药物的最低抑菌浓度(MIC)与它们在刃天青平板中的MIC进行比较,并与在MGIT和7H11琼脂上单一浓度的氧氟沙星敏感性进行比较,此外还对gyrAB基因进行了测序。

结果与结论

在所有方法中,将氧氟沙星的临界值设定为2mg/L,左氧氟沙星为1mg/L以及莫西沙星和加替沙星为0.5mg/L时,在固体培养基和MGIT方法之间观察到了一些不一致性,但这往往可以通过临界值附近的MIC来解释。罗氏培养基(LJ)和刃天青平板之间的高度不一致表明,目前在刃天青法中应用的所有氟喹诺酮类药物的临界值应该降低,并且颜色的微小变化(从蓝色到紫色)应被视为有意义的。在所有检测中,所有药物的高水平耐药与gyrA突变的存在密切相关,这支持了最近的研究结果,即氟喹诺酮类药物耐药性应在不同浓度下进行检测,因为耐药水平较低的患者可能继续从高剂量氟喹诺酮类药物治疗中获益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e61/4830418/562ae3e02f84/dkv49901.jpg

相似文献

1
Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.
J Antimicrob Chemother. 2016 May;71(5):1233-40. doi: 10.1093/jac/dkv499. Epub 2016 Feb 6.
5
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
J Antimicrob Chemother. 2010 Aug;65(8):1551-61. doi: 10.1093/jac/dkq202. Epub 2010 Jun 11.
6
Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods.
Chemotherapy. 2006;52(4):190-5. doi: 10.1159/000093486. Epub 2006 May 22.
8
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
Antimicrob Agents Chemother. 2009 Oct;53(10):4498-500. doi: 10.1128/AAC.00287-09. Epub 2009 Aug 17.
9
Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2015 Sep;59(9):5427-34. doi: 10.1128/AAC.00662-15. Epub 2015 Jun 22.

引用本文的文献

2
Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of .
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0105124. doi: 10.1128/aac.01051-24. Epub 2024 Oct 29.
4
Molecular Analysis of Anti-Tuberculosis Drug Resistance of Isolated in the Republic of Korea.
Antibiotics (Basel). 2023 Aug 17;12(8):1324. doi: 10.3390/antibiotics12081324.
5
Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria.
Microbiol Spectr. 2023 Feb 14;11(1):e0323822. doi: 10.1128/spectrum.03238-22. Epub 2022 Dec 8.
6
and intracellular inhibitory activities of nosiheptide against .
Front Microbiol. 2022 Jul 26;13:926361. doi: 10.3389/fmicb.2022.926361. eCollection 2022.
8
Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis.
Ann Clin Microbiol Antimicrob. 2021 Oct 13;20(1):73. doi: 10.1186/s12941-021-00478-z.

本文引用的文献

1
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
J Antimicrob Chemother. 2016 Feb;71(2):314-23. doi: 10.1093/jac/dkv360. Epub 2015 Nov 24.
2
The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
Microbiol Spectr. 2014 Aug;2(4):MGM2-0009-2013. doi: 10.1128/microbiolspec.MGM2-0009-2013.
3
Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis.
Emerg Microbes Infect. 2014 Mar;3(3):e19. doi: 10.1038/emi.2014.21. Epub 2014 Mar 12.
4
A four-month gatifloxacin-containing regimen for treating tuberculosis.
N Engl J Med. 2014 Oct 23;371(17):1588-98. doi: 10.1056/NEJMoa1315817.
7
Mechanisms of fluoroquinolone monoresistance in Mycobacterium tuberculosis.
FEMS Microbiol Lett. 2014 Apr;353(1):40-8. doi: 10.1111/1574-6968.12401.
9
High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
Antimicrob Agents Chemother. 2014 Jun;58(6):3270-5. doi: 10.1128/AAC.02066-13. Epub 2014 Mar 31.
10
Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis.
Int J Tuberc Lung Dis. 2014 Jan;18(1):39-43. doi: 10.5588/ijtld.13.0307.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验